KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Goodwill (2017 - 2025)

Novartis Ag's Goodwill history spans 9 years, with the latest figure at $25.6 billion for Q4 2025.

  • For Q4 2025, Goodwill rose 3.28% year-over-year to $25.6 billion; the TTM value through Dec 2025 reached $25.6 billion, up 3.28%, while the annual FY2025 figure was $25.6 billion, 3.28% up from the prior year.
  • Goodwill for Q4 2025 was $25.6 billion at Novartis Ag, up from $24.8 billion in the prior quarter.
  • Across five years, Goodwill topped out at $29.6 billion in Q4 2021 and bottomed at $23.3 billion in Q4 2023.
  • The 5-year median for Goodwill is $25.6 billion (2025), against an average of $26.5 billion.
  • The largest annual shift saw Goodwill fell 20.34% in 2023 before it increased 6.06% in 2024.
  • A 5-year view of Goodwill shows it stood at $29.6 billion in 2021, then fell by 0.99% to $29.3 billion in 2022, then decreased by 20.34% to $23.3 billion in 2023, then grew by 6.06% to $24.8 billion in 2024, then rose by 3.28% to $25.6 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Goodwill are $25.6 billion (Q4 2025), $24.8 billion (Q4 2024), and $23.3 billion (Q4 2023).